Disseminated cutaneous sporotrichosis
ICD-10 B44.1 is a billable code used to indicate a diagnosis of disseminated cutaneous sporotrichosis.
Disseminated cutaneous sporotrichosis is a fungal infection caused by the dimorphic fungus Sporothrix schenckii. This condition typically presents with skin lesions that can vary in appearance, including papules, nodules, and ulcers, often resembling other skin infections. The infection usually begins at the site of trauma or injury, where the fungus enters the body, and can spread to other areas of the skin, leading to a disseminated form. Patients may experience systemic symptoms such as fever and malaise, particularly if they are immunocompromised. The condition is more prevalent in individuals with weakened immune systems, such as those with HIV/AIDS, diabetes, or those undergoing immunosuppressive therapy. Diagnosis is typically confirmed through culture or histopathological examination of the lesions. Treatment involves antifungal medications, with itraconazole being the first-line therapy. In severe cases, amphotericin B may be required. Early diagnosis and treatment are crucial to prevent complications and improve patient outcomes.
Detailed clinical notes on the patient's immune status, lesion characteristics, and treatment plan.
Patients presenting with skin lesions and a history of immunosuppression.
Ensure thorough documentation of any co-morbid conditions that may affect treatment.
Photographic evidence of lesions, biopsy results, and treatment response.
Patients with chronic skin lesions that do not respond to standard treatments.
Document the duration and progression of lesions for accurate coding.
Used when extensive lesions require surgical intervention.
Document the extent of debridement and the condition of the lesions.
Ensure that the procedure is justified based on the severity of the infection.
The primary treatment is itraconazole, which is effective in managing the infection. In severe cases, amphotericin B may be necessary.
